Detailed price information for Agilent Technologies (A-N) from The Globe and Mail including charting and trades.

Emerging research in cellular reprogramming, gene editing, and regenerative medicine is driving interest in preventive longevity medicine. Some researchers argue aging may be treated as a modifiable ...

Drug delivery researchers have vastly improved the potential of genetic therapies by overcoming the challenge of consistently getting genes and gene-editing tools where they need to be within cells.

Looking for a biopharma job in Cambridge? Check out the BioSpace list of six companies hiring life sciences professionals like you.

Researchers simulated nearly every molecule in a bacterial cell — and then watched the cell grow and reproduce.

ARTHEx Biotech, a clinical-stage biotechnology company advancing RNA-based therapeutics for neuromuscular disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast ...

During the fourth quarter, the Harbor Health Care ETF returned 10.43% (NAV), underperforming the Russell 3000® Growth Health Care Index, which returned 16.71%.

The following segment was excerpted from the Harbor Health Care ETF Q4 2025 Commentary.During the fourth quarter, the Harbor Health Care ETF ...

Aplantex and Investissement Québec are pleased to announce a partnership to boost the deployment of Aplantex's innovative green biotechnology. Under this partnership, Investissement Québec provides ...

Veteran CRO executive and investor brings clinical research leadership and deep pharma networks to the Barcelona-based ...

People often compare the genome to a computer's program, with the cell using its genetic code to process environmental inputs and produce appropriate responses. Subscribe to our newsletter for the ...